Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio
Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology designed to deliver potent anticancer...
Search results for "ADC payload"
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells and deliver targeted radiation.
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’
The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
Alteogen to Present Subcutaneous ADC Formulation Research at International Forum in June
Alteogen announced on the 23rd that it will present research results regarding subcutaneous dosing for antibody-drug...
LigaChemBio Receives Milestone from Czech Sotio Biotech
LigaChem Biosciences announced on the 9th that it will receive milestone payments based on successful product...
1